Asfotase Alfa: Frontier Drugs For The Treatment Of Juvenile Hypophosphatemia
Asfotase alfa is sold under the brand Strensiq and is a medication used to treat hypophosphatasia that occurs during the perinatal/infant and adolescent periods.
Hypophosphatasia (HPP) is a rare genetic metabolic disorder in which patients lack alkaline phosphatase (ALP), leading to abnormal bone mineralization and symptoms such as skeletal dysplasia, fractures, and bone pain.
As a recombinant human alkaline phosphatase replacement therapy, asfotase alfa provides new therapeutic hope for HPP patients, significantly improving their bone health and quality of life.
What Is Hypophosphatasia (HPP)?
Hypophosphatasia (HPP) is a genetic disease caused by a lack of ALP enzyme activity, mainly manifested as skeletal dysplasia, fractures, dental problems, and muscle weakness.
The severity of this condition varies, with some patients experiencing bone deformities at birth, while some adult patients may show symptoms at a later age.
Due to the crucial role of ALP enzyme in bone mineralization, the lack of ALP leads to obstacles in the bone mineralization process, ultimately resulting in complications such as bone fragility and frequent fractures.
Asfotase Alfa: Innovative Treatment Options
Strensiq Asfotase Alfa is a recombinant human alkaline phosphatase that improves bone mineralization and promotes bone development by replacing deficient ALP enzymes.
The treatment mechanism of asfotaseis to directly supplement ALP enzyme, which helps enhance the mineralization ability of bones, reduce the incidence of fractures, improve bone density of patients, and thus improve bone health.
Compared with traditional treatment methods, it can address fundamental issues and provide more efficient and long-term solutions.
Asfotase Alfa: Significant Therapeutic Effect
In multiple clinical trials, asfotase alfa has demonstrated significant therapeutic effects.
Research data shows that both children and adult HPP patients receiving asfotase treatment have significantly improved bone mineralization and bone density.
Especially in patients receiving early treatment, it significantly reduces the occurrence of fracture events and improves the quality of life of patients.
For patients with severe HPP, asfotase alfa treatment not only effectively alleviates symptoms such as bone pain and deformities, but also reduces the hospitalization rate caused by fractures.
The treatment plan for it can significantly improve the bone function of patients through long-term use.
Asfotase Alfa: Convenient Treatment Plan
Asfotase is administered subcutaneously once a week.
The patient receives a standard dose of 6 mg/kg based on their weight and condition.
The treatment of asfotase usually requires continuous treatment, especially in pediatric patients, and early treatment can significantly reduce the occurrence of skeletal complications.
After the treatment begins, the doctor will adjust according to the patient’s response to ensure the best treatment effect.
Asfotase Alfa: Side Effects And Safety
Asfotase alfa is usually well tolerated by patients, and common side effects include injection site reactions (such as redness or pain), headache, fever, muscle pain, etc.
These side effects are usually mild or moderate and gradually alleviate during the treatment process.
A small number of patients may experience allergic reactions or worsening bone pain, so during the treatment process, patients need to regularly check liver and kidney function as well as bone health.
Asfotase Alfa: Bringing New Hope To HPP Patients
The approval of asfotase alfa has brought new treatment options for patients with global hypophosphatasia (HPP), especially for those who were previously unable to effectively treat, it provides a more precise and efficient treatment plan.
By supplementing the lack of alkaline phosphatase, asfotase alfa not only improves patients’ bone health but also helps them regain confidence and ability in daily life.
Summary
As a recombinant human alkaline phosphatase alternative therapy, asfotase alfa provides an innovative and effective treatment option for patients with hypophosphatasia (HPP).
By supplementing ALP enzymes, asfotase alfa significantly increased bone density and mineralization, reduced the risk of fractures and improved the quality of life of patients.
In the future, with the widespread use of this drug, more HPP patients will benefit from it, improving their bone health and extending their normal lifetime.
However, DengYue’s efforts to increase the affordability of the medicine are critical to ensuring that more patients benefit from it. So please feel free to inquiry us to buy Asfotase Alfa.
Information from DengYueMedicine, China Medicine Wholesaler offers this information as a guide, not a substitute for professional medical advice. Consult your doctor before any treatment.
